CD7 CAR-T cell
Cell therapy
CD7 CAR-T cell is one of 41 biologic programs targeting Acute Leukemia. It is currently in development.
1
Indications
2
Total Trials
2
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
173 competitors in Acute Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Oncaspar
SServier
Phase 3
Purinethol
SStason
Phase 3
Levaquin
WWim Janssens
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety1 trial
Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07476027·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD7 CAR-T cell. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]